Table 4 Non-hematologic adverse events
Any, n (%) | Grade ≥ 3, n (%) | |
|---|---|---|
Daratumumab IRR | ||
Cycle 1 (N = 31) | 15 (48.4) | 3 (9.7) |
Cycle 2 (N = 29) | 1 (3.4) | 0 |
Cycle 3 (N = 25) | 0 | 0 |
During DARA consolidation | 0 | 0 |
Nausea | 7 (22.6) | 1 (3.2) |
Dyspepsia | 4 (12.9) | 0 |
Diarrhea | 4 (12.9) | 0 |
Stomatitis | 4 (12.9) | 0 |
Constipation | 3 (9.7) | 0 |
Hypertension | 3 (9.7) | 1 (3.2) |
Anorexia | 2 (6.5) | 0 |
Peripheral sensory neuropathy | 2 (6.5) | 0 |
Hyperglycemia | 1 (3.2) | 1 (3.2) |
Treatment related death | 1 (3.1) | NA |